DGIdb - CLOPIDOGREL Drug Record

CLOPIDOGREL chembl:CHEMBL1771 Approved

Alternate Names:

SR-25990
PLAVIX
CLOPIDOGREL
R 130964
R-130964
ISCOVER
GREPID
SR 25990
PLAVIX&REG
SR-25990C
CLOPIDOGRELUM
(+)-CLOPIDOGREL
chemidplus:113665-84-2
rxcui:32968
chembl:CHEMBL1771
drugbank:00758
pubchem.compound:60606

Drug Info:

Year of Approval	1997
Drug Class	antithrombotic agents
Drug Indications	antithrombotic
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antiplatelet agent

(3 More Sources)

Publications:

Zhao Z et al., 2016, Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis., Eur J Clin Pharmacol
Tarkiainen EK et al., 2015, Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans., Clin Pharmacol Ther
Xie C et al., 2014, The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease., Pharmacogenet Genomics
Zhu HJ et al., 2013, Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation., J Pharmacol Exp Ther
Savi et al., 2006, The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts., Proc. Natl. Acad. Sci. U.S.A.
van Gestel et al., 2003, In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability., Arterioscler. Thromb. Vasc. Biol.
Wihlborg et al., 2004, ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels., Arterioscler. Thromb. Vasc. Biol.
Taubert et al., 2004, Pharmacokinetics of clopidogrel after administration of a high loading dose., Thromb. Haemost.
Gladding et al., 2008, The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial., JACC Cardiovasc Interv
Dorsam et al., 2003, Clopidogrel: interactions with the P2Y12 receptor and clinical relevance., Hematology
Herbert et al., 2003, P2Y12, a new platelet ADP receptor, target of clopidogrel., Semin Vasc Med
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Wang et al., 2004, P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells., BMC Immunol.
Shuvalova YA et al., 2012, Association between polymorphisms of eNOS and GPx-1 genes, activity of free-radical processes and in-stent restenosis., Mol Cell Biochem
Tornio A et al., 2014, Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions., Clin Pharmacol Ther
Kupstyte N et al., 2015, Effect of clinical factors and gene polymorphism of CYP2C192, 17 and CYP4F2*3 on early stent thrombosis., Pharmacogenomics
Tatarunas V et al., 2014, The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy., Blood Coagul Fibrinolysis
Hou X et al., 2018, CYP2C19 and ABCB1 genetic polymorphisms correlate with the recurrence of ischemic cardiovascular adverse events after clopidogrel treatment., J Clin Lab Anal
Danielak D et al., 2017, Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite., Eur J Clin Pharmacol
Olędzki S et al., 2017, Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention., Eur J Clin Pharmacol
Zhai Y et al., 2017, Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease., Eur J Clin Pharmacol
Su J et al., 2017, The risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han population., PLoS One
Saydam F et al., 2017, The CYP2C192 and CYP2C1917 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study., Basic Clin Pharmacol Toxicol
Zhang HZ et al., 2017, CYP2C19 but not CYP2B6, CYP3A4, CYP3A5, ABCB1, PON1 or P2Y12 genetic polymorphism impacts antiplatelet response after clopidogrel in Koreans., Blood Coagul Fibrinolysis
Calderón-Cruz B et al., 2015, C3435T polymorphism of the ABCB1 gene is associated with poor clopidogrel responsiveness in a Mexican population undergoing percutaneous coronary intervention., Thromb Res
So DY et al., 2016, A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study., Pharmacogenomics J
Wang XQ et al., 2015, Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome., Gene
Karaźniewicz-Łada M et al., 2015, Impact of common ABCB1 polymorphism on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites., J Clin Pharm Ther
Latkovskis G et al., 2014, Role of genetic factors on the effect of additional loading doses and two maintenance doses used to overcome clopidogrel hyporesponsiveness., Medicina (Kaunas)
Cresci S et al., 2014, Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction., Circ Cardiovasc Genet
Viviani Anselmi C et al., 2013, Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease., JACC Cardiovasc Interv
Zhang L et al., 2013, Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients., Thromb Res
Carlquist JF et al., 2013, Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes., Thromb Haemost
Tang XF et al., 2013, Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention., Eur J Clin Pharmacol
Su J et al., 2012, ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis., PLoS One
Wu H et al., 2012, Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China., Pharmacogenet Genomics
Verschuren JJ et al., 2013, Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction., Int J Cardiol
Chen DY et al., 2012, Paraoxonase-1 is not a major determinant of stent thrombosis in a Taiwanese population., PLoS One
Price MJ et al., 2012, Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study., J Am Coll Cardiol
Bonello L et al., 2012, Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade., Thromb Res
Delaney JT et al., 2012, Predicting clopidogrel response using DNA samples linked to an electronic health record., Clin Pharmacol Ther
Jeong YH et al., 2011, Effect of CYP2C192 and 3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin., Circ Cardiovasc Interv
Cayla G et al., 2011, Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis., JAMA
Simon T et al., 2011, Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction., Clin Pharmacol Ther
Kassimis G et al., 2012, CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention., Thromb Res
Rideg O et al., 2011, Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention., Pharmacogenomics
Wallentin L et al., 2010, Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial., Lancet
Mega JL et al., 2010, Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis., Lancet
Jeong YH et al., 2010, Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study., JACC Cardiovasc Interv
Simon T et al., 2009, Genetic determinants of response to clopidogrel and cardiovascular events., N Engl J Med
Taubert D et al., 2006, Impact of P-glycoprotein on clopidogrel absorption., Clin Pharmacol Ther
Xiang Q et al., 2017, Genetic Variants of PEAR1 are Associated with Platelet Function and Antiplatelet Drug Efficacy: A Systematic Review and Meta-Analysis., Curr Pharm Des
Yao Y et al., 2016, Association of PEAR1 genetic variants with platelet reactivity in response to dual antiplatelet therapy with aspirin and clopidogrel in the Chinese patient population after percutaneous coronary intervention., Thromb Res
Lewis JP et al., 2013, Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes., Circ Cardiovasc Genet
Floyd CN et al., 2014, The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta-analysis., Br J Clin Pharmacol
Motovska Z et al., 2009, High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial., Blood Coagul Fibrinolysis
Cooke GE et al., 2006, Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination., J Am Coll Cardiol
Angiolillo DJ et al., 2004, PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation., Blood Coagul Fibrinolysis
Abell LM et al., 2011, Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro., J Pharmacol Exp Ther
Sangkuhl K et al., 2011, Platelet aggregation pathway., Pharmacogenet Genomics
Giusti B et al., 2008, Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment., Atherosclerosis
Lepäntalo A et al., 2006, Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients., Thromb Haemost
Angiolillo DJ et al., 2005, Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene., Am J Cardiol
Angiolillo DJ et al., 2004, 807 C/T Polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment., Blood Coagul Fibrinolysis

CLOPIDOGREL ITGA2

Interaction Score: 4.64

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22940005 17157856 16493486 16214444 15205592

Sources:
PharmGKB
CLOPIDOGREL PEAR1

Interaction Score: 3.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28820077 26962983 23392654

Sources:
PharmGKB
CLOPIDOGREL N6AMT1

Interaction Score: 3.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CLOPIDOGREL CES1P1

Interaction Score: 3.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24535487

Sources:
PharmGKB
CLOPIDOGREL P2RY12

Interaction Score: 2.65

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name Plavix

Novel drug target Established target

Trial Name CGT-2168

PMIDs:
16835302 12615691 15308557 15269827 19463375 14668029 15199474 11752352 15291969

Sources:
TdgClinicalTrial TEND TTD
CLOPIDOGREL B4GALT2

Interaction Score: 1.55

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CLOPIDOGREL ITGB3

Interaction Score: 1.55

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23834376 22028352 19530321 19106083 16458133 15166949

Sources:
PharmGKB
CLOPIDOGREL CES1

Interaction Score: 1.41

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27450232 25704243 24535487 23275066

Sources:
PharmGKB
CLOPIDOGREL CYP4F2

Interaction Score: 1.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25712182 24418943

Sources:
PharmGKB
CLOPIDOGREL ABCB1

Interaction Score: 0.46

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29397568 28914344 28589365 28378058 28358842 28135763 27380588 26362473 25850030 25542807 25430046 25060201 24762860 24535487 24262617 23726091 23364775 23150151 23056288 22990067 22940005 22723959 22624833 22285300 22190063 22045970 22028352 21918510 21831410 21806387 20801498 20801494 20650435 19106083 17112805

Sources:
PharmGKB
CLOPIDOGREL NOS3

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22890915

Sources:
PharmGKB
CLOPIDOGREL CYP2C8

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24971633

Sources:
PharmGKB
CLOPIDOGREL CYP3A5

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21828263 20938371

Sources:
DTC PharmGKB
CLOPIDOGREL PTGS1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22940005

Sources:
PharmGKB
CLOPIDOGREL CYP2B6

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CLOPIDOGREL CYP2C19

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC FDA
CLOPIDOGREL CYP2C9

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CLOPIDOGREL CYP1A2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CLOPIDOGREL CYP2D6

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CLOPIDOGREL CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: CLOPIDOGREL
- Version: 01-August-2011
Alternate Names:

CLOPIDOGREL Primary Drug Name

Drug Info:

Drug Class antithrombotic agents

Year of Approval 1997

Publications:
TdgClinicalTrial: CLOPIDOGREL
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antiplatelet agent

Drug Class Small Molecule

FDA Approval approved

Publications:

PharmGKB: clopidogrel

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Zhu HJ et al., 2013, Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation., J Pharmacol Exp Ther

Zhao Z et al., 2016, Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis., Eur J Clin Pharmacol

Tarkiainen EK et al., 2015, Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans., Clin Pharmacol Ther

DTC: CLOPIDOGREL
- Version: 02-September-2020
Alternate Names:

CHEMBL1771 ChEMBL Drug ID

Drug Info:

Publications:
TTD: Clopidogrel
- Version: 2020.06.01
Alternate Names:

D0N0TZ TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1771
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
FDA: Clopidogrel
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Trial Name	Plavix
Novel drug target	Established target
Trial Name	CGT-2168

CLOPIDOGREL Drug Record

CLOPIDOGREL chembl:CHEMBL1771 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22940005 17157856 16493486 16214444 15205592

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28820077 26962983 23392654

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24535487

Sources: PharmGKB

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name Plavix Novel drug target Established target Trial Name CGT-2168

PMIDs: 16835302 12615691 15308557 15269827 19463375 14668029 15199474 11752352 15291969

Sources: TdgClinicalTrial TEND TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23834376 22028352 19530321 19106083 16458133 15166949

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27450232 25704243 24535487 23275066

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25712182 24418943

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22890915

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24971633

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21828263 20938371

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22940005

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality:

n/a

PMIDs:
22940005 17157856 16493486 16214444 15205592

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28820077 26962983 23392654

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24535487

Sources:
PharmGKB

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name Plavix

Novel drug target Established target

Trial Name CGT-2168

PMIDs:
16835302 12615691 15308557 15269827 19463375 14668029 15199474 11752352 15291969

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23834376 22028352 19530321 19106083 16458133 15166949

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27450232 25704243 24535487 23275066

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25712182 24418943

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22890915

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24971633

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21828263 20938371

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22940005

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC FDA

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

CLOPIDOGREL Primary Drug Name

Drug Info:

Drug Class antithrombotic agents

Year of Approval 1997

Drug Info:

Drug Indications antiplatelet agent

Drug Class Small Molecule

FDA Approval approved

Alternate Names:

CHEMBL1771 ChEMBL Drug ID

Alternate Names:

D0N0TZ TTD Drug ID